Study on the Effectiveness and Safety of Cevostamab in Patients with Relapsed or Hard-to-Treat Multiple Myeloma

Inclusion Criteria

• Have a confirmed diagnosis of multiple myeloma based on standard criteria.
• Show signs of disease progression after the last treatment, as determined by the study doctor.
• Have previously received certain treatments targeting BCMA and are not responding to three main types of myeloma drugs.
• Be in good general health with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of at least 12 weeks.
• Agree to undergo specific tests and procedures, including bone marrow samples.
• Have recovered from side effects of previous cancer treatments to a mild level.
• Women of childbearing potential must agree to use effective birth control during the study and for at least 5 months after the last dose of cevostamab.
• Men must agree to use condoms and avoid donating sperm during the study and for at least 2 months after the last dose of certain medications.

Exclusion Criteria

• Unable to stay in the hospital as required by the study.
• Pregnant or breastfeeding, or planning to become pregnant during the study or shortly after.
• Have previously been treated with cevostamab or similar drugs.
• Have received certain other cancer treatments recently.
• Have a history of severe allergic reactions to similar treatments.
• Have other serious health conditions, such as autoimmune diseases or certain infections.
• Have had another type of cancer within the last 2 years, except for certain low-risk cancers.
• Have significant heart or lung disease.
• Have active infections or have recently been treated for infections.
• Have a history of drug or alcohol abuse within the last year.
• Have any medical condition that the study doctor believes would make participation unsafe or affect the study results.